DTIL Precision BioSciences Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting

   Multiple Oral Presentations and Posters to Demonstrate Differentiated Attributes of ARCUS® Genome Editing Platform for Efficient Gene Insertion and Gene Knockout

   New Primary Hyperoxaluria Type 1 (PH1) Preclinical Data Demonstrate a Robust ARCUS Nuclease Optimization Process Leading to 98% Knockdown of HAO1 Protein in Non-human Primates (NHP)

   Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical data will be presented this week on ARCUS genome editing including two oral presentations and two posters at the American Society of Gene & Cell Therapy (ASGCT), May 16-19, 2022 at the Walter E. Washington Convention…

   View Full Article
2. 12 May 2022 Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

   Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS^®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan"). The inducement awards consist of options to purchase ("stock option") an aggregate of 401,905 shares of Precision's common stock, par value $0.000005 (the "Common Stock"), which stock options were granted among four employees who commenced employment on March 14, 2022. Each of the stock options were granted under…

   View Full Article
3. 09 May 2022 Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update

   - PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022

   - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years

   - Preclinical In Vivo Gene Editing Data for Primary Hyperoxaluria Type 1 and Chronic Hepatitis B Accepted for Presentation at the 2022 Annual American Society of Gene and Cell Therapy Meeting

   Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS^®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

   "We continue to focus on execution and build on the utility of ARCUS as a premier genome…

   View Full Article
4. 02 May 2022 Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting

   - Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS^® gene editing therapies

   Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS^®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene & Cell Therapy (ASGCT) and will be presented as posters and oral presentations at the upcoming annual meeting on May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.

   Details for the poster and oral presentations can be accessed on the ASGCT website at https://annualmeeting.asgct.org/abstracts…

   View Full Article
5. 02 May 2022 Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022

   Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022

   Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2022 and provide a business update on May 9, 2022. Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022.

   Details for the virtual presentation are below:

   H.C. Wainwright Global Investment Conference
   Date: Tuesday, May 24, 2022
   Time: On-demand session available at 7:00 AM ET

   A live webcast of the presentation…

   View Full Article